O'Brien R J, Geiter L J, Lyle M A
Division of Tuberculosis Control, Centers for Disease Control, Atlanta, Georgia 30333.
Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):821-6. doi: 10.1164/ajrccm/141.4_Pt_1.821.
During the period October 1983 through January 1988, the Centers for Disease Control (CDC) provided the experimental drug rifabutin (ansamycin LM427) to 406 patients with severe, progressive Mycobacterium avium complex pulmonary disease who had been unresponsive to standard therapy. Selected patients were randomly assigned to doses of 150, 300, or 450 mg rifabutin. Choice of companion drugs was left to the treating physicians. In the analysis of data from this program, we examined the relationship between response to treatment, as measured by bacteriologic sputum conversion, survival, weight gain, improvement in respiratory symptoms, and subjective assessment of clinical improvement, and a variety of patient and treatment variables. Although in some of the analyses a higher rifabutin dose appeared to be associated with sputum conversion, survival, and clinical improvement, the drug did not have a marked effect on outcome. The role of rifabutin in the treatment of this disease will best be assessed in a controlled clinical trial.
在1983年10月至1988年1月期间，疾病控制中心（CDC）为406例患有严重、进行性鸟分枝杆菌复合群肺部疾病且对标准治疗无反应的患者提供了实验性药物利福布汀（安莎霉素LM427）。选定的患者被随机分配接受150、300或450毫克利福布汀的剂量。辅助药物的选择由治疗医生决定。在对该项目数据的分析中，我们研究了以痰菌转阴、生存率、体重增加、呼吸道症状改善以及临床改善的主观评估来衡量的治疗反应与各种患者和治疗变量之间的关系。尽管在一些分析中，较高剂量的利福布汀似乎与痰菌转阴、生存率和临床改善有关，但该药物对治疗结果并没有显著影响。利福布汀在这种疾病治疗中的作用最好在一项对照临床试验中进行评估。
